Literature DB >> 17083916

Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity.

Luca Vangelista1, Renato Longhi, Francesca Sironi, Vincenzo Pavone, Paolo Lusso.   

Abstract

HIV initiates its infectious cycle by docking to CD4 and a chemokine receptor, most commonly CCR5. RANTES, a natural CCR5 ligand, is a potent inhibitor of HIV-1. Despite the lack of structural information on the RANTES-CCR5 complex, determinants of HIV blockade were previously identified within the RANTES N-loop and beta1-strand regions. A prototype N-loop/beta1-strand peptide, named R11-29, contains two terminal hydrophobic stretches separated by a central hydrophilic region. Here, the role of the terminal hydrophobic clusters was investigated by means of amino acid substitutions or deletions. Most hydrophobic residues in these clusters were shown to be fundamental for the anti-HIV activity. However, increasing the hydrophobicity of the two clusters using non-natural amino acids did not significantly improve the potency of the peptides. These results may provide instrumental knowledge for the rational design of RANTES-derivative molecules with increased anti-HIV activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083916      PMCID: PMC1850098          DOI: 10.1016/j.bbrc.2006.10.090

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Tissue sulfhydryl groups.

Authors:  G L ELLMAN
Journal:  Arch Biochem Biophys       Date:  1959-05       Impact factor: 4.013

2.  Structure of a V3-containing HIV-1 gp120 core.

Authors:  Chih-chin Huang; Min Tang; Mei-Yun Zhang; Shahzad Majeed; Elizabeth Montabana; Robyn L Stanfield; Dimiter S Dimitrov; Bette Korber; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Peter D Kwong
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

Review 3.  HIV and the chemokine system: 10 years later.

Authors:  Paolo Lusso
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

4.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

Authors:  J M Kilby; S Hopkins; T M Venetta; B DiMassimo; G A Cloud; J Y Lee; L Alldredge; E Hunter; D Lambert; D Bolognesi; T Matthews; M R Johnson; M A Nowak; G M Shaw; M S Saag
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

Review 5.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.

Authors:  G B Fields; R L Noble
Journal:  Int J Pept Protein Res       Date:  1990-03

6.  Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

Authors:  Michael M Lederman; Ronald S Veazey; Robin Offord; Donald E Mosier; Jason Dufour; Megan Mefford; Michael Piatak; Jeffrey D Lifson; Janelle R Salkowitz; Benigno Rodriguez; Andrew Blauvelt; Oliver Hartley
Journal:  Science       Date:  2004-10-15       Impact factor: 47.728

7.  Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors.

Authors:  S J Siciliano; T E Rollins; J DeMartino; Z Konteatis; L Malkowitz; G Van Riper; S Bondy; H Rosen; M S Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

8.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

9.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

Authors:  O Nussbaum; C C Broder; E A Berger
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Structure of an unliganded simian immunodeficiency virus gp120 core.

Authors:  Bing Chen; Erik M Vogan; Haiyun Gong; John J Skehel; Don C Wiley; Stephen C Harrison
Journal:  Nature       Date:  2005-02-24       Impact factor: 49.962

View more
  8 in total

1.  Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.

Authors:  Paolo Lusso; Luca Vangelista; Raffaello Cimbro; Massimiliano Secchi; Francesca Sironi; Renato Longhi; Marina Faiella; Ornella Maglio; Vincenzo Pavone
Journal:  FASEB J       Date:  2011-01-03       Impact factor: 5.191

Review 2.  Rational design of novel HIV-1 entry inhibitors by RANTES engineering.

Authors:  Luca Vangelista; Massimiliano Secchi; Paolo Lusso
Journal:  Vaccine       Date:  2008-01-10       Impact factor: 3.641

3.  Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5.

Authors:  Massimiliano Secchi; Lia Vassena; Sébastien Morin; Dominique Schols; Luca Vangelista
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

Review 4.  Peptide and protein-based inhibitors of HIV-1 co-receptors.

Authors:  Horst A von Recum; Jonathan K Pokorski
Journal:  Exp Biol Med (Maywood)       Date:  2013-05

5.  Endogenous Peptide Inhibitors of HIV Entry.

Authors:  Mirja Harms; Manuel Hayn; Fabian Zech; Frank Kirchhoff; Jan Münch
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  NMR mapping of RANTES surfaces interacting with CCR5 using linked extracellular domains.

Authors:  Einat Schnur; Naama Kessler; Yuri Zherdev; Eran Noah; Tali Scherf; Fa-Xiang Ding; Svetlana Rabinovich; Boris Arshava; Victoria Kurbatska; Ainars Leonciks; Alexander Tsimanis; Osnat Rosen; Fred Naider; Jacob Anglister
Journal:  FEBS J       Date:  2013-04-02       Impact factor: 5.542

7.  Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis.

Authors:  Yerkezhan Amerzhanova; Luca Vangelista
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

8.  Rational CCL5 mutagenesis integration in a lactobacilli platform generates extremely potent HIV-1 blockers.

Authors:  Massimiliano Secchi; Valentina Grampa; Luca Vangelista
Journal:  Sci Rep       Date:  2018-01-30       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.